

SPARKLE ASSETS LIMITED
(the “**Company**”)
(Incorporated in the British Virgin Islands with limited liability)

ANNOUNCEMENT

We refer to the US\$400,000,000 6.875% Senior Notes due 2020 issued by the Company on 30 January 2013 and guaranteed by, *inter alias*, Fosun International Limited (the “**Parent Guarantor**”).

The Parent Guarantor has released the attached announcement dated 9 November 2016 on The Stock Exchange of Hong Kong Limited.

BY ORDER OF THE BOARD

Qin Xuetang
Director

9 November 2016

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN 复星
復星國際有限公司
FOSUN INTERNATIONAL LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

**PROGRESS UPDATE ANNOUNCEMENT
ON
DISCLOSEABLE TRANSACTION
PROPOSED NON-PUBLIC ISSUANCE OF
NEW A SHARES BY FOSUN PHARMA AND
POSSIBLE DEEMED DISPOSAL OF EQUITY INTEREST
IN FOSUN PHARMA**

Reference is made to the announcement of Fosun International Limited (the “**Company**”) dated 17 April 2015 (the “**Announcement**”) in relation to the proposed non-public issuance of new A shares by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”), a subsidiary of the Company. Capitalized terms used in this announcement have the same meanings as defined in the Announcement, unless the context requires otherwise.

The board of directors of the Company is pleased to announce that the non-public issuance by Fosun Pharma (the “**Issuance**”) has been completed on 8 November 2016.

Fosun Pharma has issued a total of 100,436,681 A shares at the Subscription Price of RMB22.90 per A share to the subscribers. The net proceeds raised (deducting related expenses of the Issuance incurred) amounted to RMB2,275,249,558.22. After the completion of the Issuance, the equity interest in Fosun Pharma held by the Company (through Fosun High Technology, a wholly-owned subsidiary of the Company) has been diluted from 40.02% to 38.36% of the total issued share capital of Fosun Pharma. As the Company continues to have control over Fosun Pharma, Fosun Pharma continues to be accounted for as a subsidiary of the Company in accordance with the prevailing accounting standards under the HKFRS and its operating results will continue to be consolidated in the financial statements of the Company upon completion of the Issuance.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

9 November 2016

As at the date of this announcement, the executive directors are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Ding Guoqi, Mr. Qin Xuetao, Mr. Chen Qiyu and Mr. Xu Xiaoliang; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang and Mr. Yang Chao.